Oncologia

Seguimento de longo prazo de um estudo randomizado | Lesões de colo do útero pré-cancerosas, causadas por tipos de HPV não preveníveis por vacina, após uso de vacina contra HPV bivalente AS04.

29 Ago, 2022 | 15:50h

Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comentário: Clinical Unmasking May Cause Increased Rates of High-Grade Cervical Neoplasia From Non–Vaccine Preventable HPV – Cancer Network

 

Comentário no Twitter

Virological replacement & clinical unmasking are two phenomena of interest following #HPVvaccination. We show that clinical unmasking might attenuate long-term reductions in cervical precancer following successful implementation of HPV vax programs in highly screened populations https://t.co/Z7dGQNG1kG

— Monica Sierra (@MonicaSSierra) June 14, 2022

 

---

M-A | Incidência e mortalidade de cânceres não definidores de Aids entre pessoas que vivem com HIV.

29 Ago, 2022 | 14:01h

Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis – eClinicalMedicine

Conteúdo relacionado: Study: Cancer Patients with HIV Infection Have Worse Outcomes

 

---

Estudo de caso-controle | Avaliação de desfechos 1 ano após detecção de câncer gástrico precoce entre pacientes de alto risco.

29 Ago, 2022 | 13:52h

Assessment of Outcomes From 1-Year Surveillance After Detection of Early Gastric Cancer Among Patients at High Risk in Japan – JAMA Network Open

Comentário: Intensive Endoscopy Might Not Be One-and-Done for Gastric Cancer Surveillance — High-risk group had similar new lesion detection rates initially and at 15 months – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter

Among patients with a high risk of gastric cancer, 1-year surveillance was warranted even after intensive endoscopic examination using both white light and narrow-band imaging. https://t.co/3KIghTavjb

— JAMA Network Open (@JAMANetworkOpen) August 19, 2022

 

---

Estudo de braço único fase 2 | Quimioterapia neoadjuvante, excisão e observação para câncer retal não avançado.

29 Ago, 2022 | 13:42h

Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results – Journal of Clinical Oncology

 

Comentário do autor no Twitter (fio – clique para saber mais)

Pleased to share our ⁦@CDNCancerTrials⁩ NEO Trial results: 79% of patients with cT1-3bN0 #rectalcancer had organ sparing therapy with 3 mo of FOLFOX/CAPOX and transanal surgery. ⁦@drcarl_vancouvr⁩ ⁦@JCO_ASCO⁩ ⁦⁦⁦@OncoAlert⁩ https://t.co/gfcywHk7Y0

— Hagen Kennecke (@HKennecke) August 18, 2022

 

---

Recomendações de consenso | Padronização da avaliação patológica do carcinoma mamário após quimioterapia neoadjuvante.

29 Ago, 2022 | 13:41h

Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy: Recommendations From the I-SPY Pathology Working Group – Archives of Pathology & Laboratory Medicine

 

---

Lesões de células mamárias fusiformes: algoritmo diagnóstico.

29 Ago, 2022 | 13:40h

Spindle Cell Lesions of the Breast: A Diagnostic Algorithm – Archives of Pathology & Laboratory Medicine

 

---

M-A | Erlotinibe com bevacizumabe vs. erlotinibe isolado em pacientes com câncer de pulmão de não pequenas células avançado e EGFR-positivo.

23 Ago, 2022 | 16:53h

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials – BMJ Open

 

---

Estudo randomizado | Efetividade da terapia com etoposídeo e cisplatina vs. irinotecano e cisplatina para pacientes com carcinoma neuroendócrino avançado do sistema digestório.

23 Ago, 2022 | 16:33h

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial – JAMA Oncology

 

Comentário no Twitter

JCOG1213 (TOPIC NEC), the first randomized phase III trial in advanced neuroendocrine carcinoma of the digestive system, shows no significant difference in overall survival for etoposide+cisplatin versus irinotecan+cisplatin therapy https://t.co/JTELRlzTzi #GICSM pic.twitter.com/AQT8U4yd3l

— JAMA Oncology (@JAMAOnc) August 18, 2022

 

---

Estudo de braço único fase 2 | Atividade do cabazitaxel no lipossarcoma dediferenciado localmente avançado metastático ou inoperável.

23 Ago, 2022 | 16:31h

Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) – JAMA Oncology (gratuito por tempo limitado)

Comentário convidado: Optimizing Histology-Specific Clinical Trials in Soft-Tissue Sarcoma—Are We There Yet? – JAMA Oncology (gratuito por tempo limitado)

 

---

Estudo | Quase metade das mortes globais por câncer se devem a fatores de risco, sendo tabagismo, uso de álcool e IMC alto os que mais contribuem.

23 Ago, 2022 | 16:28h

The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 – The Lancet

Comunicado de imprensa: The Lancet: Almost half of global cancer deaths are due to risk factors, with smoking, alcohol use, and high BMI the greatest contributors – Institute for Health Metrics and Evaluation

 

Comentário no Twitter (fio – clique para saber mais)

NEW #GBDstudy research from 2010-2019 found that a majority of attributable #Cancer DALYs globally were from behavioral risk factors. The top 3 behavioral risk factors for cancer burden were: #smoking 🚬, #alcohol 🍺, & high #BMI. @TheLancet »https://t.co/qPzDKzfLda pic.twitter.com/LnkvlkDHgA

— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) August 18, 2022

 

---